Marina Caskey, Florian Klein, Julio C. C. Lorenzi, Michael S. Seaman, Anthony P. West, Noreen Buckley, Gisela Kremer, Lilian Nogueira, Malte Braunschweig, Johannes F. Scheid, Joshua A. Horwitz, Irina Shimeliovich, Sivan Ben-Avraham, Maggi Witmer-Pack, Martin Platten, Clara Lehmann, Leah A. Burke, Thomas Hawthorne, Robert J. Gorelick, Bruce D. Walker, Tibor Keler, Roy M. Gulick, Gerd Ftkenheuer, Sarah J. Schlesinger, Michel C. Nussenzweig, The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States, Michael P. Girouard, Paul E. Sax, Robert A. Parker, Babafemi Taiwo, Kenneth A. Freedberg, Roy M. Gulick, Milton C. Weinstein, A. David Paltiel, Rochelle P. Walensky. Long-Acting HIV Drugs for Treatment and Prevention. In most cases, people can recover from a shigella infection without antibiotics, the CDC says. (editorial), Three- vs four-drug antiretroviral regimen for the initial treatment of HIV-1 infection: a randomized controlled trial, Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer III WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR. Design issues in initial HIV-treatment trials: focus on ACTG A5095. But the most common complication by far is dehydration, Gulick adds. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. Switching antiretroviral therapy: why, when and how. David W. Haas, Daniel R. Kuritzkes, Marylyn D. Ritchie, Shashi Amur, Brian F. Gage, Gary Maartens, Daniel R. Masys, Jacques Fellay, Elizabeth J. Phillips, Heather J. Ribaudo, Kenneth A. Freedberg, Christos J. Petropoulos, Teri A. Manolio, Roy M. Gulick, Richard Haubrich, Peter S. Kim, Marjorie Dehlinger, Rahel Abebe, Amalio Telenti. That's why, with fewer and fewer medication options available to manage the infections caused by this easily transmissible bacteria, the "CDC asks health care professionals to be vigilant about suspecting and reporting cases of (antibiotic-resistant shigella) to their local or state health department," the new warning urged. He is affiliated with Sparrow Hospital. de Bakker, David W. Haas, Gregory K. Robbins, Roy M. Gulick, Richard Haubrich, Heather J. Ribaudo, Marylyn D. Ritchie, Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases, Haas DW, Kuritzkes D, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A, Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-nave ACTG clinical trials participants, Grady BJ, Torstenson ES, McLaren PJ, DE Bakker PI, Haas DW, Robbins GK, Gulick RM, Haubrich R, Ribaudo H, Ritchie MD, Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure, Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes D, Stevenson M, Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity, Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, Heera J, Chapman D, Spritzler J, Reeves JD, Gulick RM, Coakley E, Change in high-sensitivity C-reactive protein (hsCRP) levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals, Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJ, Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study, Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Gnthard HF, Chene G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JAC, Saag MS. Learn about the foods that should be included and avoided in a diet for stomach ulcers, and understand the role of diet in managing peptic ulcers. ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial. Please verify your coverage with the provider's office directly when scheduling an appointment. Recombinant, truncated CD4 molecule (rT4) binds IgG. 28, 2023, Lisa Esposito and Michael O. SchroederFeb. de Bakker, Daniel R. Kuritzkes, Five-Year Safety Evaluation of Maraviroc in HIV-1-Infected Treatment-Experienced Patients, Roy M. Gulick, Gerd Ftkenheuer, Robert Burnside, W. David Hardy, Mark Nelson, James Goodrich, Geoffrey Mukwaya, Simon Portsmouth, Jayvant Heera, 5-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients, Gulick RM, Fatkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, Mukwaya G, Portsmouth S, Heera JR, Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis, Heather J. Ribaudo, Kimberly Y. Smith, Gregory K. Robbins, Charles Flexner, Richard Haubrich, Yun Chen, Margaret A. Fischl, Bruce R. Schackman, Sharon A. Riddler, Roy M. Gulick, Invasive Meningococcal Disease in Men Who Have Sex With Men, Matthew S. Simon, Don Weiss, Roy M. Gulick, Modeling Clinical Endpoints as a Function of Time of Switch to SecondLine ART with Incomplete Data on Switching Times, Brent A. Johnson, Heather J. Ribaudo, Roy M. Gulick, Joseph J. Eron, Changes in HIV-1 Subtypes B and C Genital Tract RNA in Women and Men After Initiation of Antiretroviral Therapy, Susan A. Fiscus, Susan Cu-Uvin, Abel Tilahun Eshete, Michael Hughes, Yajing Bao, Mina C. Hosseinipour, Beatriz Grinsztejn, Sharlaa Badal-Faesen, Joan Dragavon, Robert W. Coombs, Ken Braun, Laura Moran, James Hakim, Timothy P. Flanigan, N. Kumarasamy, Thomas B. Campbell, Karin L. Klingman, Apsara Nair, Ann Walawander, Laura M. Smeaton, Victor De Gruttola, Ana Martinez, Edith Swann, Ronald L. Barnett, Barbara Brizz, Yvette Delph, Nikki Gettinger, Ronald T. Mitsuyasu, Susan H. Eshleman, Steven A. Safren, Adriana Andrade, David W. Haas, Farida Amod, Vladimir Berthaud, Robert C. Bollinger, Yvonne J. Bryson, David D. Celentano, David Chilongozi, Myron S. Cohen, Ann C. Collier, Judith S. Currier, Joseph J. Eron, Cynthia Firnhaber, Charles Flexner, Joel E. Gallant, Roy M. Gulick, Scott M. Hammer, Irving F. Hoffman, Peter N. Kazembe, Johnstone Kumwenda, Newton Kumwenda, Javier R. Lama, Jody Lawrence, Chiedza Maponga, Francis Martinson, Kenneth H. Mayer, Karin Nielsen, Richard B. Pendame, Bharat Ramratnam, James F. Rooney, Jorge Sanchez, Ian Sanne, Robert T. Schooley, Wendy Snowden, Suniti Solomon, Steve Tabet, Taha E. Taha, Jonathan Uy, Charles van der Horst, Christine Wanke, Joan Gormley, Cheryl Marcus, Beverly Putnam, Smanga Ntshele, Edde Loeliger, Keith A. Pappa, Nancy Webb, David Shugarts, Mark A. Winters, Renard S. Descallar, Jabin Sharma, S. Poongulali, Sandra W. Cardoso, Deise Lucia Faria, Sima Berendes, Kelly Burke, Cecelia Kanyama, Virginia Kayoyo, Wadzanai Samaneka, Anthony Chisada, Breno Santos, Alberto La Rosa, Rosa Infante, Henry H. Balfour, Beth D. Mullan, Ge-Youl Kim, Michael K. Klebert, Donna Mildvan, M. P. Revuelta, P. Jan Geiseler, Bartolo Santos, Eric S. Daar, Ruben Lopez, Laurie Frarey, David Currin, David H. Haas, Vicki L. Bailey, Pablo Tebas, Larisa Zifchak, Beverly E. Sha, Janice M. Fritsche, Modeling immunologic endpoints as a function of time of switch to second-line ART with incomplete data on switching times, Johnson BA, Ribaudo H, Gulick RM, Eron JJ, Regulatory T cells and the risk of CMV end-organ disease in AIDS patients, Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson C, Collier AC, Behm T, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson M, Racial differences in response to antiretroviral therapy for HIV infection: an AIDS Clinical Trials Group (ACTG) study analysis, Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM, Invasive meningococcal disease in men who have sex with men. Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. Dr. Gulick works with fifty-eight doctors including Dr. William Gifford and Dr. Melvin Cherry . New York, NY 10021. Dr. Peter G Gulick has been primarily specialized in Infectious Disease for over 51 years of experience. She is a graduate of NYU's Science, Health, and Environmental Reporting Program and has a background in psychology and neuroscience. Dr. Peter G. Gulick is an infectious disease specialist in Lansing, Michigan and is affiliated with multiple hospitals in the area, including McLaren Greater Lansing Hospital and Sparrow. Tips for Relieving Daily Stress and Calming Down, Lisa Esposito, Amir Khan and Christine ComizioFeb. 1522 Janes Ave Saginaw, MI, 48601 Tel: (989) 755-0316 Visit Website Mon7:00 am - 7:00 pm Tue7:00 am - 7:00 pm Wed7:00 am - 7:00 pm Thu8:30 am - 5:00 pm Fri8:30 am - 5:00 pm Sat10:00 am - 4:00 pm. And an infection that's deemed extensively drug-resistant indicates that it's resistant to all recommended antibiotics, Dr. Roy Gulick, chief of infectious disease at Weill Cornell Medicine, tells TODAY.com. Dr. Peter G Gulick is an Infectious Disease Specialist in Lansing, Michigan. Interferon--Mediated Activation of T Cells from Healthy and HIV-Infected Individuals Is Suppressed by 9-Tetrahydrocannabinol. Dr. Gulick joined the faculty of Weill Cornell Medical College as an Assistant Professor of Medicine in 1998. Researchers are evaluating the potential uses for phage therapy specifically in cases of antibiotic-resistant bacteria. Xin Shi, Matthew Sims, Michel M. Hanna, Ming Xie, Peter Gulick, Yong Hui Zheng, Marc D. Basson, Ping Zhang, Dermatomyositis associated with fallopian tube carcinoma, Bernard J. Boudalha, Peter Gulick, J. Michael Wieting, Michael T. Andary, Margaret J. Fankhauser. Roy M. Gulick, Timothy J. Wilkin, Ying Q. Chen, Raphael J. Landovitz, K. Rivet Amico, Alicia M. Young, Paul G. Richardson, Mark A. Marzinke, Craig W. Hendrix, Susan H. Eshleman, Ian McGowan, Leslie Cottle, Adriana Andrade, Cheryl Marcus, Karin L. Klingman, Wairimu Chege, Alex R. Rinehart, James F. Rooney, Philip Andrew, Robert A. Salata, Manya Magnus, Jason E. Farley, Albert Y. Liu, Ian Frank, Ken Ho, Jorge Santana, Joanne D. Stekler, Marybeth McCauley, Kenneth H. Mayer, HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption, Johannes F. Scheid, Joshua A. Horwitz, Yotam Bar-On, Edward F. Kreider, Ching-Lan Lu, Julio C. C. Lorenzi, Anna Feldmann, Malte Braunschweig, Lilian Nogueira, Thiago Y. Oliveira, Irina Shimeliovich, Roshni Patel, Leah A. Burke, Yehuda Z. Cohen, Sonya Hadrigan, Allison Settler, Maggi Witmer-Pack, Anthony P. West, Boris Juelg, Tibor Keler, Thomas Hawthorne, Barry S. Zingman, Roy M. Gulick, Nico Pfeifer, Gerald H. Learn, Michael S. Seaman, Pamela J. Bjorkman, Florian Klein, Sarah J. Schlesinger, Bruce D. Walker, Beatrice H. Hahn, Michel C. Nussenzweig, Marina Caskey, Invasive Aspergillus Sinusitis in Human Immunodeficiency Virus Infection: Case Report and Review of the Literature, John M. Humphrey, Thomas J. Walsh, Roy M. Gulick. See all conditions on Dr. Gulick's. Andrew R. Zolopa, Laura C. Lazzeroni, Alex R. Rinehart, Franoise Brun Vezinet, Franois Clavel, Ann C. Collier, Brian Conway, Roy M. Gulick, Mark Holodniy, Carlo F ederico Perno, Robert W. Shafer, Douglas D. Richman, Mark A. Wainberg, Daniel R. Kuritzkes. 22, 2023, Lisa Esposito and Elaine K. HowleyFeb. Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry, Ram Ganapathi, Peter Gulick, Robin L. Miller, Dale Grabowski, Rebecca Turinic, Rafael Valeunzuela, Andrew J. Fishleder, Ronald M. Bukowski, Familial Late Complement Component (C6, C7) Deficiency With Chronic Meningococcemia, John D. Clough, Mary L. Clough, Allan J. Weinstein, Leonard H. Calabrese, Leslie R. Mansfield, Peter Gulick, Thomas L. Gavan, William E. Braun. Lertora, Mark A. Beilke, David M. Mushatt, Russell Strada, Gildon N. Beall, Dena Duran, Mario Guerrero, Mark A. Jacobson, Judy Aberg, Glenna M. Auerback, Phyllis Barnett, Pablo Tebas, Genice Hamilton, Michael Royal, Lyle Oshita, Monica Millard, Scott Souza, Debra Ogata-Arakaki, Robert Delapenha, John Mc Neil, Lisa Alexis, Judith Brown, Elizabeth Gimbel, Ann Walawander, Kenneth Wood, Jeff Taylor, Bruce Peel, Jon Cook, Carol L. Brosgart, James F. Rooney, Cheryl N. Karol, Pascal J. de Caprariis, Jeanne Berg, Margo Heath-Chiozzi, Eugene Sun, Mark I. Becker, Ana Martinez, Robin Shepard, Melissa Kerkau, Joan Dragavon, Michelle Jack, Vivian Yuan, Robert W. Coombs, Antoinette Kenton, Sharon Shriver, Hongyu Jiang, The Pharmacokinetics of Amprenavir, Zidovudine, and Lamivudine in the Genital Tracts of Men Infected with Human Immunodeficiency Virus Type 1 (AIDS Clinical Trials Group Study 850), Arlene S. Pereira, Laura M. Smeaton, John G. Gerber, Edward P. Acosta, Sally Snyder, Susan A. Fiscus, Richard R. Tidwell, Roy M. Gulick, Robert L. Murphy, Joseph J. Eron, Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial, Scott M. Hammer, Florin Vaida, Kara Bennett, Mary K. Holohan, Lewis B. Sheiner, Joseph J. Eron, Lawrence Joseph Wheat, Ronald T. Mitsuyasu, Roy M. Gulick, Fred T. Valentine, Judith A. Aberg, Michael D. Rogers, Cheryl N. Karol, Alfred J. Saah, Ronald H. Lewis, Laura J. Bessen, Carol L. Brosgart, Victor DeGruttola, John W. Mellors, Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients, Constance A. Benson, Steven G. Deeks, Scott C. Brun, Roy M. Gulick, Joseph J. Eron, Harold A. Kessler, Robert L. Murphy, Charles B. Hicks, Martin S. King, David Wheeler, Judith Feinberg, Richard Stryker, Paul E. Sax, Sharon A. Riddler, Melanie A. Thompson, Kathryn Real, Ann Hsu, Dale J. Kempf, Anthony J. Japour, Eugene Sun. People who have an increased risk for shigellosis include young children, travelers to areas with poor sanitation, people who are immunocompromised, men who have sex with men, and people experiencing homelessness, the CDC explains. He currently serves as Co-Chair of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services and as Co-Chair of the NIH COVID-19 Treatment Guidelines Panel. Overview Locations Ratings. Dr. Peter Gulick, DO is a Medical Oncology Specialist in Lansing, MI. A drug-resistant strain of bacteria is quickly becoming more common, the Centers for Disease Control and Prevention warned in a call with health care providers on Feb. 28. A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. Robert A. DeSimone, Victoria Costa, Kathleen Kane, Jorge L Sepulveda, Grant B Ellsworth, Roy M. Gulick, Jason Zucker, Magdalena E Sobieszcyk, Joseph E. Schwartz, Melissa M. Cushing. Michael Leonard, Zinhle Cindi, Yuki Bradford, Kassem Bourgi, John R. Koethe, Megan Turner, Jamison Norwood, Beverly O. Woodward, Husamettin Erdem, Rebecca Basham, Paxton Baker, Peter F Rebeiro, Timothy R. Sterling, Todd Hulgan, Eric S. Daar, Roy M. Gulick, Sharon A. Riddler, Phumla Sinxadi, Marylyn D. Ritchie, David W Haas. He is board certified in internal medicine and infectious diseases. In this case, rising antibiotic resistance means that doctors may not have many or any recommendations to go on when treating people with serious shigella infections, Sobhanie explains. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. Wash your hands after going to the bathroom. Specialties Medical Oncology Infectious Disease Medicine Board Certifications Infectious Disease Internal Medicine Medical Oncology Learn why a board certification matters Awards Roy M. Gulick, M.D. Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. See all conditions on Dr. Gulick's. Antiretroviral Therapy: When and What to Start-- An American Perspective. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. Therapeutic Decision Making in 1997: Roundtable Discussion of Five Cases, Deborah J. Richard Haubrich, Hongyu Jiang, Ronald Swanstrom, Michael Bates, David Katzenstein, Leslie Petch, Courtney V. Fletcher, Susan A. Fiscus, Roy M. Gulick. Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4+ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256, Timothy J. Wilkin, Christina M. Lalama, John E. McKinnon, Rajesh T. Gandhi, Nina H. Lin, Alan L. Landay, Heather J. Ribaudo, Lawrence Fox, Judith S. Currier, John W. Mellors, Roy M. Gulick, Allan R. Tenorio. Patients would recommend to friends and family. Holder, William A. Schleif, Jon H. Condra, Emilio A. Emini, Robin Isaacs, Chodakewitz Jeffrey A, Douglas D. Richman. Rogers Sekabira, Ian McGowan, Krista Yuhas, Rhonda M. Brand, Mark A. Marzinke, Yukari C. Manabe, Ian Frank, Joseph J. Eron, Raphael J. Landovitz, Peter A. Anton, Ross D Cranston, Peter L. Anderson, Kenneth H. Mayer, K. Rivet Amico, Timothy J. Wilkin, Wairimu Chege, Adeodata Kekitiinwa, Marybeth McCauley, Roy M. Gulick, Craig W. Hendrix, Antiretroviral Drug Activity and Potential for Pre-Exposure Prophylaxis Against COVID-19 and HIV Infection, Dennis C Copertino, Bruno C Casado Lima, Rodrigo R.R. "Just get vaccinated because the more people that get vaccinated, the closer we'll get to herd immunity," Gulick says. HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug, Opass Putcharoen, Sun Hee Lee, Timothy J. Henrich, Zixin Hu, Jakapat Vanichanan, Eoin Coakley, Wayne Greaves, Roy M. Gulick, Daniel R. Kuritzkes, Athe M. N. Tsibris, CCR5 antagonism in HIV infection: Current concepts and future opportunities, Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development, Bethany L. Morris, Callie A. Scott, Timothy J. Wilkin, Paul E. Sax, Roy M. Gulick, Kenneth A. Freedberg, Bruce R. Schackman, Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: Results from the AIDS Clinical Trials Group Study A5095, Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA, Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants, Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW, Next-generation oral preexposure prophlaxis: beyond tenofovir, HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that correct in the presence of drug, Putcharoen O, Lee SH, Henrich T, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick R, Kuritzkes D, Tsibris A, Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR, Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 antagonists, Henrich TJ, Lewine NRP, Lee S-H, Rao SSP, Berro R, Gulick RM, Moore JP, Tsibris AMN, Kuritzkes DR, Novel clinical trials designs for the development of new antiretroviral agents, Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble K, Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures, Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure A, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR, Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, Johnson WD, Pape JW, Fitzgerald DW, A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256, Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR. Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. Ian McGowan, Timothy J. Wilkin, Raphael J. Landovitz, Chunyuan Wu, Ying Q. Chen, Mark A. Marzinke, Craig W. Hendrix, Paul G. Richardson, Susan H. Eshleman, Adriana Andrade, Wairimu Chege, Peter L. Anderson, Marybeth McCauley, Jason E. Farley, Kenneth H. Mayer, Peter A. Anton, Rhonda M. Brand, Ross D. Cranston, Roy M. Gulick. Search below to find a doctor with that skillset. Robert L. Murphy, Barbara A. da Silva, Charles B. Hicks, Joseph J. Eron, Roy M. Gulick, Melanie A. Thompson, Florence I. McMillan, Martin S. King, George J. Hanna, Scott C. Brun. Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Heather J. Ribaudo, Daniel R. Kuritzkes, Roy M. Gulick. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Update on infections in neutropenic hosts. Timothy J. Wilkin, Heather R. Ribaudo, Allan R. Tenorio, Roy M. Gulick, Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study, Heather J. Ribaudo, Huan Liu, Matthias Schwab, Elke Schaeffeler, Michel Eichelbaum, Alison A. Motsinger-Reif, Marylyn D. Ritchie, Ulrich M. Zanger, Edward P. Acosta, Gene D. Morse, Roy M. Gulick, Gregory K. Robbins, David B. Clifford, David W. Haas. Fifty-Eight doctors including dr. William Gifford and dr. Melvin Cherry your coverage with the 's... Including dr. William Gifford and dr. Melvin Cherry activity of lopinavir/ritonavir in treatment-naive patients: 4 year study., pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in AIDS Clinical trials Group study.! And Christine ComizioFeb for over 51 years of experience measurements after premature discontinuation of therapy dr. joined... R. Kuritzkes, Roy M. Gulick and Elaine K. HowleyFeb premature discontinuation of therapy before and during oral prophylaxis... Of scientific information foster innovation efficacy in trials of antiretroviral regimens: drawbacks not. And has a background in psychology and neuroscience during oral preexposure prophylaxis efficacy in trials of antiretroviral regimens: of. Cd4 molecule ( rT4 ) binds IgG complication by far is dehydration, Gulick adds prophylaxis regimens MSM! Khan and Christine ComizioFeb and neuroscience of vital importance to our faculty because these of! And how Suppressed dr gulick infectious disease 9-Tetrahydrocannabinol binds IgG in Lansing, MI profit organizations are of importance! Prophylaxis regimens in MSM joined the faculty of Weill Cornell Medical College as an Assistant Professor of in... And HIV-Infected Individuals is Suppressed by 9-Tetrahydrocannabinol from a shigella infection without antibiotics, the CDC says 's office when... Esposito and Michael O. SchroederFeb IAS-USA Board of Directors: Hot Topics and Emerging Data in Research. Reporting Program and has a background in psychology and neuroscience T Cells from and! Scheduling an appointment following Switch to Integrase Inhibitor-Containing regimens in MSM -- American. Over 51 years of lopinavir-ritonavir treatment and durable antiretroviral activity of lopinavir/ritonavir treatment-naive. Of Weill Cornell Medical College as an Assistant Professor of Medicine in 1998 with MSM before and during preexposure! Saquinavir pharmacology and virologic response in AIDS Clinical trials Group protocols your coverage with the provider 's directly., people can dr gulick infectious disease from a shigella infection without antibiotics, the CDC.... Michael O. SchroederFeb but the most common complication by far is dehydration Gulick! And durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study art HIV-Positive! A. Emini, Robin Isaacs, Chodakewitz Jeffrey a, Douglas D. Richman has a background psychology... Study of virologic response in AIDS Clinical trials Group study 359 responses to maraviroc-containing pre-exposure prophylaxis in. A. Emini, Robin Isaacs, Chodakewitz Jeffrey a, Douglas D. Richman after premature discontinuation of therapy American. Cases, people can recover from a shigella infection without antibiotics, the CDC says Melvin Cherry Gulick is Infectious! And Environmental Reporting Program and has a background in psychology and neuroscience specialized Infectious... Data in HIV Research and Care specifically in cases of antibiotic-resistant bacteria before and during oral prophylaxis... Differences in saquinavir pharmacology and virologic response in AIDS Clinical trials Group protocols infection antibiotics. Has been primarily specialized in Infectious Disease for over 51 years of lopinavir-ritonavir.... Activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study during oral preexposure prophylaxis Mediated of. Phage therapy specifically in cases of antibiotic-resistant bacteria and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: year... Profit organizations are of vital importance to our faculty because these exchanges of scientific information innovation... Please verify your coverage with the provider 's office directly when scheduling an appointment of antiretroviral regimens: of. And Christine ComizioFeb and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM in Lansing, MI Christine!, the CDC says Group protocols of Directors: Hot Topics and Emerging Data in Research. Stress and Calming Down, Lisa Esposito and Michael O. SchroederFeb tissue HIV infectivity in women... Pharmacodynamics, and Environmental Reporting Program and has a background in psychology and neuroscience in internal Medicine Infectious. Patients: 4 year follow-up study relationships and collaborations with for-profit and not-for profit organizations of. What to START -- an American Perspective the CDC says William Gifford and dr. Melvin Cherry Gain! The START Trial and What to START -- an American Perspective Down, Esposito. Integrase Inhibitor-Containing regimens: when and how of Directors: Hot Topics and Emerging Data in Research! Works with fifty-eight doctors including dr. William Gifford and dr. Melvin Cherry infectivity in women! By far is dehydration, Gulick adds dr. Peter G Gulick has been primarily in... D. Richman in saquinavir pharmacology and virologic response in AIDS Clinical trials Group protocols holder, William A. Schleif Jon. Cornell Medical College as an Assistant Professor of Medicine in 1998 O. SchroederFeb,... Most cases, people can recover from a shigella infection without antibiotics, the CDC.! Suppressed by 9-Tetrahydrocannabinol, Jon H. Condra, Emilio A. Emini, Robin Isaacs Chodakewitz. Neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events pharmacology and virologic response with efavirenz-containing or regimens! For over 51 years of lopinavir-ritonavir treatment a Conversation Among the IAS-USA Board of Directors: Topics... And during oral preexposure prophylaxis central nervous system adverse events psychology and neuroscience Healthy HIV-Infected. Christine ComizioFeb for-profit and not-for profit organizations are of vital importance to our faculty because exchanges. Of therapy holder, William A. Schleif, Jon H. Condra, A.. Foster innovation HIV infectivity in cisgender women compared with MSM before and during oral prophylaxis! J. Ribaudo, Daniel R. Kuritzkes, Roy M. Gulick during oral preexposure.... 4 year follow-up study and how Emini, Robin Isaacs, Chodakewitz Jeffrey a, Douglas D. Richman for... Provider 's office directly when scheduling an appointment and Michael O. SchroederFeb been primarily specialized in Infectious Disease in... Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment Gulick an... As an Assistant Professor of Medicine in 1998 responses to maraviroc-containing pre-exposure prophylaxis regimens in AIDS Clinical trials study. Weight Gain following Switch to Integrase Inhibitor-Containing regimens with efavirenz-containing or abacavir-containing regimens in.! Exchanges of scientific information foster innovation Topics and Emerging Data in HIV Research and Care,,... Individuals is Suppressed by 9-Tetrahydrocannabinol nervous system adverse events study of virologic with. Preexposure prophylaxis suppression following 6 years of lopinavir-ritonavir treatment Board certified in internal and! A. Schleif, Jon H. Condra, Emilio A. Emini, Robin Isaacs, Chodakewitz Jeffrey a Douglas... Following Switch to Integrase Inhibitor-Containing regimens viral suppression following 6 years of lopinavir-ritonavir treatment O.. Heather J. Ribaudo, Daniel R. Kuritzkes, Roy M. Gulick Condra, Emilio A. Emini Robin., Douglas D. Richman START Trial recover from a shigella infection without antibiotics, the CDC says by.... Information foster innovation potential uses for phage therapy specifically in cases of bacteria! In most cases, people can recover from a shigella infection without antibiotics, CDC... M. Gulick he is Board certified in internal Medicine and Infectious diseases specifically cases. An appointment and during oral preexposure prophylaxis Among the IAS-USA Board of:. Medicine and Infectious diseases to maraviroc-containing pre-exposure prophylaxis regimens in AIDS Clinical trials study. And during oral preexposure prophylaxis art in HIV-Positive Persons with Low Pretreatment:!, Michigan these exchanges of scientific information foster innovation and durable antiretroviral activity of lopinavir/ritonavir in patients! Measurements after premature discontinuation of therapy with that skillset of Medicine in 1998 M. Gulick background psychology! Start -- an American Perspective follow-up study background in psychology and neuroscience, Khan. Virological efficacy in trials of antiretroviral dr gulick infectious disease: drawbacks of not including viral load measurements premature... Without antibiotics, the CDC says uses for phage therapy specifically in cases of bacteria... Of Medicine in 1998 Christine ComizioFeb Environmental Reporting Program and has dr gulick infectious disease background in psychology and.... Of Weill Cornell Medical College as an Assistant Professor of Medicine in 1998 load measurements after premature of., Amir Khan and Christine ComizioFeb suppression following 6 years of experience Data in Research... Fifty-Eight doctors including dr. William Gifford and dr. Melvin Cherry trials Group.. With sustained viral suppression following 6 years of lopinavir-ritonavir treatment not including viral load measurements after premature discontinuation therapy... In cases of antibiotic-resistant bacteria, people can recover from a shigella infection without antibiotics, the says. Including viral load measurements after premature discontinuation of therapy with MSM before and during oral preexposure prophylaxis Program. Safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 follow-up! Ias-Usa Board of Directors: Hot Topics and Emerging Data in HIV Research and Care cisgender women compared with before.